In a filing, United Therapeutics Corp revealed its Director SULLIVAN LOUIS W unloaded Company’s shares for reported $9.78 million on Dec 18 ’24. In the deal valued at $373.22 per share,26,209 shares were sold. As a result of this transaction, SULLIVAN LOUIS W now holds 5,051 shares worth roughly $1.82 million.
Then, LOUIS W. SULLIVAN bought 26,209 shares, generating $9,783,214 in total proceeds.
Before that, BENKOWITZ MICHAEL sold 10,000 shares. United Therapeutics Corp shares valued at $3,701,377 were divested by the PRESIDENT AND COO at a price of $370.14 per share. As a result of the transaction, BENKOWITZ MICHAEL now holds 0 shares, worth roughly $0.0.
Morgan Stanley downgraded its United Therapeutics Corp [UTHR] rating to an Equal-weight from a an Overweight in a research note published on July 11, 2024; the price target was increased to $321 from $310. A number of analysts have revised their coverage, including Goldman’s analysts, who increased its forecast for the stock in mid February from “a Sell” to “a Neutral”. Leerink Partners began covering UTHR with “an Outperform” recommendation on February 05, 2024. Wells Fargo started covering the stock on December 08, 2023. It rated UTHR as “an Overweight”.
Price Performance Review of UTHR
On Friday, United Therapeutics Corp [NASDAQ:UTHR] saw its stock fall -0.16% to $359.58. Over the last five days, the stock has lost -0.62%. United Therapeutics Corp shares have risen nearly 63.53% since the year began. Nevertheless, the stocks have risen 59.45% over the past one year. While a 52-week high of $417.82 was reached on 11/08/24, a 52-week low of $208.62 was recorded on 02/08/24. SMA at 50 days reached $370.64, while 200 days put it at $316.31.
Levels Of Support And Resistance For UTHR Stock
The 24-hour chart illustrates a support level at 357.08, which if violated will result in even more drops to 354.57. On the upside, there is a resistance level at 362.99. A further resistance level may holdings at 366.40. The Relative Strength Index (RSI) on the 14-day chart is 43.55, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -7.46, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 72.28%. Stochastics %K at 20.92% indicates the stock is a holding.
How much short interest is there in United Therapeutics Corp?
A steep rise in short interest was recorded in United Therapeutics Corp stocks on 2024-11-29, dropping by -0.22 million shares to a total of 2.08 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-31 was 2.3 million shares. There was a decline of -10.62%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 06, 2022 when UBS began covering the stock and recommended ‘”a Buy”‘ rating along with a $320 price target.
